AUTHORS
Satya Sai Sri Bandi, M.B.B.S., Andre De Menezes Silva Corraes, MD2, Christoph Schaefers, MD3, Melinda Tan, MD4, Joselle M Cook, M.D.5, Saurabh Zanwar, MBBS, MD6, Ricardo Daniel Parrondo, MD7, Moritz Binder, MD, MPH8, Taxiarchis Kourelis, MD9, Rahma Warsame, MD10, Wilson Gonsalves, MD11, Morie Gertz, MD12, Prashant Kapoor, MD13, Shaji Kumar, MD14, Yi Lin Jr, MD, PhD15, Nadine Abdallah I, MD16
AFFILIATIONS
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Rochester, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Rochester, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Rochester, United States
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Rochester, United States
16 Mayo Clinic, Rochester, United States
ABSTRACT
Background: Chimeric antigen receptor (CAR) T-cell therapy is increasingly used in older adults with relapsed/refractory multiple myeloma (MM), yet the optimal approach to frailty assessment in this setting remains unclear. The International Myeloma Working Group (IMWG) frailty index is considered the gold standard for frailty assessment in MM, but is underutilized in practice due to time constraints. While the simplified frailty index is more readily available, it incorporates physician-assessed performance status, which may introduce subjectivity. The concordance between these measures and the dynamics of frailty in the CAR-T setting have not been well characterized.
Methods: We retrospectively analyzed patients with MM who underwent CAR T-cell therapy at our institution and had paired frailty assessments between 06/17/2024 and 04/02/2026. Concordance between the International Myeloma Working Group (IMWG; age, ADL/IADL, Charlson Comorbidity Index [CCI]) and simplified (age, ECOG performance status, CCI) frailty indices performed on the same day was evaluated at baseline and 1, 3, and 6 months after CAR T-cell therapy. The IMWG index was categorized as fit, intermediate-fit, or frail and dichotomized as non-frail (fit/intermediate-fit) versus frail for binary analyses; the simplified index was categorized as non-frail versus frail. Agreement was assessed using quadratic weighted Cohen's κ, Spearman's rank correlation coefficient (ρ), and exact agreement, with binary agreement evaluated using Cohen's κ. Using the binary IMWG classification as the reference standard, we calculated the accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the simplified frailty index. Longitudinal changes in frailty from baseline were categorized as stable, improved, or worsened.
Results: A total of 96 patients were included; 38 (39.6%) were female, >90% were non-Hispanic White, and the median age was 69.5 years (IQR, 63-74). At baseline, 18/96 patients (18.8%) were classified as frail by the simplified frailty index. Among 88 patients with baseline IMWG frailty data, 60 (68.2%) were fit, 21 (23.9%) intermediate-fit, and 7 (8.0%) frail.
Paired IMWG and simplified frailty assessments were available for 88 patients at baseline, 26 at 1 month, 51 at 3 months, and 34 at 6 months. Concordance between the IMWG and simplified frailty indices was high across all time points, with weighted Cohen's κ ranging from 0.650 to 0.843, Spearman's ρ from 0.719 to 0.915 (all P<0.001), and exact agreement from 65.4% to 76.5%. Binary agreement remained good (Cohen's κ, 0.519–0.605), with overall accuracy of 86.3%-88.6%. Using the IMWG index as the reference standard, the simplified frailty index identified all IMWG-frail patients (100% sensitivity and 100% negative predictive value at every time point), with specificity ranging from 84.8% to 87.7% and positive predictive value from 40.0% to 50.0%, reflecting classification of a small number of additional patients as frail.
Frailty status remained stable over the first 6 months following CAR T-cell therapy. By the simplified frailty index, frailty status was unchanged in 94.5% (86/91), 92.1% (82/89), and 90.6% (58/64) of patients at 1, 3, and 6 months, respectively; improvement from frail to non-frail occurred in two patients at each time point, while worsening from non-frail to frail occurred in 3, 5, and 4 patients, respectively. By the binary IMWG classification, frailty status remained unchanged in all paired assessments (24/24 at 1 month, 48/48 at 3 months, and 32/32 at 6 months). Using the three-category IMWG classification, only one patient transitioned from fit to intermediate-fit at 1 month, with no additional transitions observed at 3 or 6 months.
Conclusion: The simplified frailty index demonstrated high concordance with the IMWG frailty index in patients with MM undergoing CAR T-cell therapy and identified all IMWG-defined frail patients. Frailty status appeared largely stable during the first 6 months after CAR T-cell therapy, although this finding should be interpreted cautiously given attrition and the declining number of paired longitudinal assessments. Prospective studies are needed to confirm frailty trajectories and evaluate the prognostic value of both frailty measures in the CAR-T setting.
DISCLOSURES
Satya Sai Sri Bandi, M.B.B.S.: No relevant conflicts of interest to declare.